METHOD OF MODIFYING GLUCOSE ACTIVITY USING POLYPEPTIDES SELECTIVELY EXPRESSED IN FAT TISSUE

• US 20090317393A1
• Filed: 10/25/2007
• Published: 12/24/2009
• Est. Priority Date: 02/24/2003
• Status: Abandoned Application

• Current Assignee: University of Maryland Baltimore County (University of Maryland)
• Original Assignee: University of Maryland Baltimore County (University of Maryland)
• Inventors: GONG, DA-WEI, SHULDINER, ALAN, YANG, RONGZE, MCLENITHAN, JOHN
• Application Number:
  US11/924,272
• Publication Number:
  US 20090317393A1
• Time in Patent Office: Days
• US Class Current: 424/139.100
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition.

Claims

1. A method of decreasing glucose metabolism in an animal, comprising interfering with an activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3 in an animal in need of treatment, wherein upon interfering with an activity of said polypeptide, glucose metabolism in the animal is decreased.

4. The method of claim 1, wherein the interfering comprises administering a molecule that inhibits a signaling activity of the omentin polypeptide.

7. The method of claim 1, wherein the interfering comprises administering a molecule that inhibits a metabolic activity of the omentin polypeptide.

10. The method of claim 4, wherein the molecule inhibits binding of omentin to a receptor.

13. The method of claim 4, wherein the molecule is an anti-omentin antibody.

16. The method of claim 7, wherein the molecule is an anti-omentin antibody.

19. The method of claim 1, wherein the activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3 is a signaling activity or a metabolic activity.

24. The method of claim 10, wherein the molecule is an anti-omentin antibody.

2. A method of decreasing insulin activity in an animal, comprising interfering with an activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3 in an animal in need of treatment, wherein upon interfering with an activity of said polypeptide, insulin activity in the animal is decreased.

5. The method of claim 2, wherein the interfering comprises administering a molecule that inhibits a signaling activity of the omentin polypeptide.

8. The method of claim 2, wherein the interfering comprises administering a molecule that inhibits a metabolic activity of the omentin polypeptide.

11. The method of claim 5, wherein the molecule inhibits binding of omentin to a receptor.

14. The method of claim 5, wherein the molecule is an anti-omentin antibody.

17. The method of claim 8, wherein the molecule is an anti-omentin antibody.

20. The method of claim 2, wherein the activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3 is a signaling activity or a metabolic activity.

25. The method of claim 11, wherein the molecule is an anti-omentin antibody.

3. A method of treating obesity or type 2 diabetes in an animal, comprising interfering with an activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3 in an animal in need of treatment, wherein upon interfering with an activity of said polypeptide, obesity or type 2 diabetes in the animal is treated.

6. The method of claim 3, wherein the interfering comprises administering a molecule that inhibits a signaling activity of the omentin polypeptide.

9. The method of claim 3, wherein the interfering comprises administering a molecule that inhibits a metabolic activity of the omentin polypeptide.

12. The method of claim 6, wherein the molecule inhibits binding of omentin to a receptor.

15. The method of claim 6, wherein the molecule is an anti-omentin antibody.

18. The method of claim 9, wherein the molecule is an anti-omentin antibody.

21. The method of claim 3, wherein the activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3 is a signaling activity or a metabolic activity.

22. A method of decreasing glucose metabolism in an animal, comprising administering to an animal in need of treatment a molecule that inhibits a signaling activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3, wherein upon inhibition of omentin polypeptide signaling activity, glucose metabolism in the animal is decreased.

23. A method of decreasing glucose metabolism in an animal, comprising administering to an animal in need of treatment a molecule that inhibits a metabolic activity of the omentin polypeptide of SEQ ID NO:

1 or the omentin polypeptide of SEQ ID NO;

3, wherein upon inhibition of omentin polypeptide metabolic activity, glucose metabolism in the animal is decreased.